Skip to main content

Psoriasis clinical trials at UCLA

5 in progress, 2 open to eligible people

Showing trials for
  • TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

    open to eligible people ages 18 years and up

    The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.

    Los Angeles, California and other locations

  • ESK-001 in Patients with Moderate to Severe Plaque Psoriasis

    open to eligible people ages 18 years and up

    The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: - Does ESK-001 reduce the severity of people's psoriasis? - How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: - take drug every day for 24 weeks. - visit the clinic for checkups and tests. - fill out questionnaires about their psoriasis, itch severity, and change in quality of life. - be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. - provide blood and urine samples.

    Sylmar, California and other locations

  • About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

    Sorry, in progress, not accepting new patients

    The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 61 weeks.

    Los Angeles, California and other locations

  • JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

    Sorry, in progress, not accepting new patients

    The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

    Santa Monica, California and other locations

  • JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

    Sorry, in progress, not accepting new patients

    The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

    Los Angeles, California and other locations

Our lead scientists for Psoriasis research studies include .

Last updated: